-
1
-
-
84876787550
-
The epidemiology of pancreatitis and pancreatic cancer
-
23622135 10.1053/j.gastro.2013.01.068
-
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-61.
-
(2013)
Gastroenterology
, vol.144
, Issue.6
, pp. 1252-1261
-
-
Yadav, D.1
Lowenfels, A.B.2
-
2
-
-
0003964363
-
-
The American Cancer Society, Inc. Accessed 5 May 2013
-
The American Cancer Society, Inc. Cancer Facts & Figures. 2013. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2013. Accessed 5 May 2013
-
(2013)
Cancer Facts & Figures
-
-
-
3
-
-
84995748195
-
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
-
22811878 1:CAS:528:DC%2BC38XhsVOqt77E
-
Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105-19.
-
(2012)
J Gastrointest Oncol
, vol.3
, Issue.2
, pp. 105-119
-
-
Ballehaninna, U.K.1
Chamberlain, R.S.2
-
4
-
-
84891481572
-
Characteristics of the ideal tumor marker
-
D.W. Kufe R.E. Pollock R.R. Weichselbaum (eds) et al. 6 Hamilton Decker http://www.ncbi.nlm.nih.gov/books/NBK12917/
-
Bigbee W, Herberman RB. Characteristics of the ideal tumor marker. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei cancer medicine. 6th ed. Decker: Hamilton; 2003. http://www.ncbi.nlm.nih.gov/books/ NBK12917 /.
-
(2003)
Holland-Frei Cancer Medicine
-
-
Bigbee, W.1
Herberman, R.B.2
-
5
-
-
79961166826
-
Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer
-
21691750 10.1007/s00432-011-0992-2 1:CAS:528:DC%2BC3MXovVensb8%3D
-
Park JY, Kim SA, Chung JW, et al. Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol. 2011;137(8):1229-38.
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, Issue.8
, pp. 1229-1238
-
-
Park, J.Y.1
Kim, S.A.2
Chung, J.W.3
-
6
-
-
83155168484
-
Proteome-based biomarkers in pancreatic cancer
-
22171124 10.3748/wjg.v17.i44.4845 1:CAS:528:DC%2BC38XptFc%3D
-
Sun C, Rosendahl AH, Ansari D, et al. Proteome-based biomarkers in pancreatic cancer. World J Gastroenterol. 2011;17(44):4845-52.
-
(2011)
World J Gastroenterol
, vol.17
, Issue.44
, pp. 4845-4852
-
-
Sun, C.1
Rosendahl, A.H.2
Ansari, D.3
-
7
-
-
51349092847
-
Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients
-
18706098 10.1186/1471-2407-8-241
-
Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241.
-
(2008)
BMC Cancer
, vol.8
, pp. 241
-
-
Tian, M.1
Cui, Y.Z.2
Song, G.H.3
-
8
-
-
0032807639
-
Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer
-
10436798 10.1093/annonc/10.suppl-4.S107
-
Tascilar M, Caspers E, Sturm PD, et al. Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer. Ann Oncol. 1999;10 Suppl 4:107-10.
-
(1999)
Ann Oncol
, vol.10
, Issue.SUPPL. 4
, pp. 107-110
-
-
Tascilar, M.1
Caspers, E.2
Sturm, P.D.3
-
9
-
-
65449141024
-
A compendium of potential biomarkers of pancreatic cancer
-
19360088 10.1371/journal.pmed.1000046 1:CAS:528:DC%2BD1MXltFGntb8%3D
-
Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6(4):e1000046.
-
(2009)
PLoS Med
, vol.6
, Issue.4
, pp. 1000046
-
-
Harsha, H.C.1
Kandasamy, K.2
Ranganathan, P.3
-
10
-
-
84874107046
-
Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival
-
23344532 10.1097/MPA.0b013e31825b6ab0 1:CAS:528:DC%2BC3sXis1KqsrY%3D
-
Shin SH, Kim SC, Hong SM, et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013;42(2):216-22.
-
(2013)
Pancreas
, vol.42
, Issue.2
, pp. 216-222
-
-
Shin, S.H.1
Kim, S.C.2
Hong, S.M.3
-
11
-
-
70349479239
-
Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor
-
19737965 10.1158/1541-7786.MCR-08-0567 1:CAS:528:DC%2BD1MXhtFCjtbjO
-
Ozaki N, Ohmuraya M, Hirota M, et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res. 2009 Sep;7(9):1572-81.
-
(2009)
Mol Cancer Res
, vol.7
, Issue.9
, pp. 1572-1581
-
-
Ozaki, N.1
Ohmuraya, M.2
Hirota, M.3
-
12
-
-
16244384974
-
Molecular analysis of pancreatic juice: A helpful tool to differentiate benign and malignant pancreatic tumors?
-
15753605 10.1159/000082794
-
Teich N, Mossner J. Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis. 2004;22(3):235-8.
-
(2004)
Dig Dis
, vol.22
, Issue.3
, pp. 235-238
-
-
Teich, N.1
Mossner, J.2
-
13
-
-
84882261462
-
European experts consensus statement on cystic tumours of the pancreas
-
doi: 10.1016/j.dld.2013.01.010
-
Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013. doi: 10.1016/j.dld.2013.01.010.
-
(2013)
Dig Liver Dis
-
-
Del Chiaro, M.1
Verbeke, C.2
Salvia, R.3
-
14
-
-
70349862783
-
Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report
-
19690057 10.1093/annonc/mdp332 1:STN:280:DC%2BC3c7isVChug%3D%3D
-
Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441-7.
-
(2010)
Ann Oncol
, vol.21
, Issue.3
, pp. 441-447
-
-
Duffy, M.J.1
Sturgeon, C.2
Lamerz, R.3
-
15
-
-
34249310279
-
Proteomic approaches for serum biomarker discovery in cancer
-
17593616 1:CAS:528:DC%2BD2sXmslKju7s%3D
-
Maurya P, Meleady P, Dowling P, et al. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27(3A):1247-55.
-
(2007)
Anticancer Res
, vol.27
, Issue.3 A
, pp. 1247-1255
-
-
Maurya, P.1
Meleady, P.2
Dowling, P.3
-
16
-
-
34248182539
-
Comparative proteomic analysis of human pancreatic juice: Methodological study
-
17443640 10.1002/pmic.200600086 1:CAS:528:DC%2BD2sXlsVWqurg%3D
-
Zhou L, Lu Z, Yang A, et al. Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics. 2007;7(8):1345-55.
-
(2007)
Proteomics
, vol.7
, Issue.8
, pp. 1345-1355
-
-
Zhou, L.1
Lu, Z.2
Yang, A.3
-
17
-
-
7044237450
-
Comprehensive proteomic analysis of human pancreatic juice
-
15473694 10.1021/pr0499085
-
Grønborg M, Bunkenborg J, Kristiansen TZ, et al. Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res. 2004;3(5):1042-55.
-
(2004)
J Proteome Res
, vol.3
, Issue.5
, pp. 1042-1055
-
-
Grønborg, M.1
Bunkenborg, J.2
Kristiansen, T.Z.3
-
18
-
-
17844377326
-
Proteomic profiling of pancreatic cancer for biomarker discovery
-
15684406 10.1074/mcp.R500004-MCP200 1:CAS:528:DC%2BD2MXjtFCisb8%3D
-
Chen R, Pan S, Brentnall TA, et al. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics. 2005;4(4):523-33.
-
(2005)
Mol Cell Proteomics
, vol.4
, Issue.4
, pp. 523-533
-
-
Chen, R.1
Pan, S.2
Brentnall, T.A.3
-
19
-
-
84857797949
-
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer
-
21994333 10.1136/gutjnl-2011-300784 1:CAS:528:DC%2BC38XmsFOisL8%3D
-
Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61(4):582-8.
-
(2012)
Gut
, vol.61
, Issue.4
, pp. 582-588
-
-
Farrell, J.J.1
Zhang, L.2
Zhou, H.3
-
20
-
-
77949297718
-
Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles
-
20300169 10.1007/s11306-009-0178-y 1:CAS:528:DC%2BC3cXivFarsrs%3D
-
Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78-95.
-
(2010)
Metabolomics
, vol.6
, Issue.1
, pp. 78-95
-
-
Sugimoto, M.1
Wong, D.T.2
Hirayama, A.3
-
21
-
-
77249119159
-
Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer
-
19931263 10.1053/j.gastro.2009.11.010 1:CAS:528:DC%2BC3cXksVCrtro%3D
-
Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010;138(3):949-57.
-
(2010)
Gastroenterology
, vol.138
, Issue.3
, pp. 949-957
-
-
Zhang, L.1
Farrell, J.J.2
Zhou, H.3
-
22
-
-
77955965020
-
Advances in pancreatic cancer detection
-
20857621 10.1016/S0065-2423(10)51006-0 1:CAS:528:DC%2BC3cXhsFKgurvP
-
Tanase CP, Neagu M, Albulescu R, et al. Advances in pancreatic cancer detection. Adv Clin Chem. 2010;51:145-80.
-
(2010)
Adv Clin Chem
, vol.51
, pp. 145-180
-
-
Tanase, C.P.1
Neagu, M.2
Albulescu, R.3
-
23
-
-
56049114482
-
Stool testing for the early detection of pancreatic cancer: Rationale and current evidence
-
18999925 10.1586/14737159.8.6.753 1:CAS:528:DC%2BD1cXhtlKmt7%2FP
-
Haug U, Wente MN, Seiler CM, et al. Stool testing for the early detection of pancreatic cancer: rationale and current evidence. Expert Rev Mol Diagn. 2008;8(6):753-9.
-
(2008)
Expert Rev Mol Diagn
, vol.8
, Issue.6
, pp. 753-759
-
-
Haug, U.1
Wente, M.N.2
Seiler, C.M.3
-
24
-
-
84860698296
-
Stool DNA testing for the detection of pancreatic cancer: Assessment of methylation marker candidates
-
22083596 10.1002/cncr.26558 1:CAS:528:DC%2BC38XmsVWnur8%3D
-
Kisiel JB, Yab TC, Taylor WR, et al. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer. 2012;118(10):2623-31.
-
(2012)
Cancer
, vol.118
, Issue.10
, pp. 2623-2631
-
-
Kisiel, J.B.1
Yab, T.C.2
Taylor, W.R.3
-
25
-
-
80053318958
-
Serum CA 19-9 as a biomarker for pancreatic cancer - A comprehensive review
-
22693400 10.1007/s13193-011-0042-1
-
Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer - a comprehensive review. Indian J Surg Oncol. 2011;2(2):88-100.
-
(2011)
Indian J Surg Oncol
, vol.2
, Issue.2
, pp. 88-100
-
-
Ballehaninna, U.K.1
Chamberlain, R.S.2
-
26
-
-
79551626900
-
Carbohydrate markers of pancreatic cancer
-
21265800 10.1042/BST0390340 1:CAS:528:DC%2BC3MXhsVShsbk%3D
-
Szajda SD, Waszkiewicz N, Chojnowska S, et al. Carbohydrate markers of pancreatic cancer. Biochem Soc Trans. 2011;39(1):340-3.
-
(2011)
Biochem Soc Trans
, vol.39
, Issue.1
, pp. 340-343
-
-
Szajda, S.D.1
Waszkiewicz, N.2
Chojnowska, S.3
-
27
-
-
84863596203
-
CA 19-9 in pancreatic cancer: Retrospective evaluation of patients with suspicion of pancreatic cancer
-
22203495 10.1007/s13277-011-0297-8 1:CAS:528:DC%2BC38XmsF2nt7g%3D
-
Molina V, Visa L, Conill C, et al. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33(3):799-807.
-
(2012)
Tumour Biol
, vol.33
, Issue.3
, pp. 799-807
-
-
Molina, V.1
Visa, L.2
Conill, C.3
-
28
-
-
0029552495
-
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy
-
8669855 1:STN:280:DyaK283ntFeqtw%3D%3D
-
Pasanen PA, Eskelinen M, Partanen K, et al. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res. 1995;15(6B):2731-7.
-
(1995)
Anticancer Res
, vol.15
, Issue.6 B
, pp. 2731-2737
-
-
Pasanen, P.A.1
Eskelinen, M.2
Partanen, K.3
-
29
-
-
11144353917
-
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
-
15073115 10.1158/1078-0432.CCR-03-0165 1:CAS:528:DC%2BD2cXivFSqs7k%3D
-
Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386-92.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2386-2392
-
-
Koopmann, J.1
Buckhaults, P.2
Brown, D.A.3
-
30
-
-
84864965633
-
Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma
-
22461132 10.1245/s10434-012-2337-z
-
Collins AL, Rock J, Malhotra L, et al. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19(8):2673-8.
-
(2012)
Ann Surg Oncol
, vol.19
, Issue.8
, pp. 2673-2678
-
-
Collins, A.L.1
Rock, J.2
Malhotra, L.3
-
31
-
-
34548401651
-
Progress on molecular markers of pancreatic cancer
-
17762556 10.1097/MOG.0b013e3282ba5724 1:CAS:528:DC%2BD2sXpvVemsr8%3D
-
Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol. 2007;23(5):508-14.
-
(2007)
Curr Opin Gastroenterol
, vol.23
, Issue.5
, pp. 508-514
-
-
Grote, T.1
Logsdon, C.D.2
-
32
-
-
84860434801
-
Advances in biomarker research for pancreatic cancer
-
22372502 10.2174/13816128112092439 1:CAS:528:DC%2BC38XmslOnurk%3D
-
Bhat K, Wang F, Ma Q, et al. Advances in biomarker research for pancreatic cancer. Curr Pharm Des. 2012;18(17):2439-51.
-
(2012)
Curr Pharm des
, vol.18
, Issue.17
, pp. 2439-2451
-
-
Bhat, K.1
Wang, F.2
Ma, Q.3
-
33
-
-
79951833553
-
Serum biomarker panels for the detection of pancreatic cancer
-
21325298 10.1158/1078-0432.CCR-10-0248 1:CAS:528:DC%2BC3MXitVWjsrw%3D
-
Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17(4):805-16.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.4
, pp. 805-816
-
-
Brand, R.E.1
Nolen, B.M.2
Zeh, H.J.3
-
34
-
-
84877018424
-
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
-
23579210 10.1038/bjc.2013.158 1:CAS:528:DC%2BC3sXntVOrtbg%3D
-
Boeck S, Wittwer C, Heinemann V, et al. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer. 2013;108(8):1684-94.
-
(2013)
Br J Cancer
, vol.108
, Issue.8
, pp. 1684-1694
-
-
Boeck, S.1
Wittwer, C.2
Heinemann, V.3
-
35
-
-
34047250660
-
Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor
-
10.1158/0008-5472.CAN-06-3362 1:CAS:528:DC%2BD2sXivV2ns7s%3D
-
Ramachandran V, Arumugam T, Hwang RF, et al. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor. ADMR Cancer Res. 2007;67(6):2666-75.
-
(2007)
ADMR. Cancer Res.
, vol.67
, Issue.6
, pp. 2666-2675
-
-
Ramachandran, V.1
Arumugam, T.2
Hwang, R.F.3
-
36
-
-
34248187583
-
CEACAM1, a novel serum biomarker for pancreatic cancer
-
17446843 10.1097/MPA.0b013e3180333ae3 1:CAS:528:DC%2BD2sXls1Gltb0%3D
-
Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas. 2007;34(4):436-43.
-
(2007)
Pancreas
, vol.34
, Issue.4
, pp. 436-443
-
-
Simeone, D.M.1
Ji, B.2
Banerjee, M.3
-
37
-
-
33748932541
-
Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4
-
16918991 10.1111/j.1349-7006.2006.00297.x 1:CAS:528:DC%2BD28XhtFemtbnO
-
Takehara A, Eguchi H, Ohigashi H, et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006;97(11):1191-7.
-
(2006)
Cancer Sci
, vol.97
, Issue.11
, pp. 1191-1197
-
-
Takehara, A.1
Eguchi, H.2
Ohigashi, H.3
-
38
-
-
79954430750
-
Serum biomarkers for improved diagnostic of pancreatic cancer: A current overview
-
21193998 10.1007/s00432-010-0965-x
-
Bünger S, Laubert T, Roblick UJ, et al. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137(3):375-89.
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, Issue.3
, pp. 375-389
-
-
Bünger, S.1
Laubert, T.2
Roblick, U.J.3
-
39
-
-
31544450588
-
Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9
-
16428484 10.1158/1078-0432.CCR-05-0564 1:CAS:528:DC%2BD28XmtlKisg%3D%3D
-
Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12(2):442-6.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.2
, pp. 442-446
-
-
Koopmann, J.1
Rosenzweig, C.N.2
Zhang, Z.3
-
40
-
-
77949262349
-
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma
-
19789838 10.1007/s00535-009-0114-y 1:CAS:528:DC%2BC3cXpslantg%3D%3D
-
Takayama R, Nakagawa H, Sawaki A, et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol. 2010;45(1):52-9.
-
(2010)
J Gastroenterol
, vol.45
, Issue.1
, pp. 52-59
-
-
Takayama, R.1
Nakagawa, H.2
Sawaki, A.3
-
41
-
-
2442635516
-
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma
-
15006928 1:CAS:528:DC%2BD2cXhvVygtL4%3D
-
Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487-91.
-
(2004)
Cancer Epidemiol Biomarkers Prev
, vol.13
, pp. 487-491
-
-
Koopmann, J.1
Fedarko, N.S.2
Jain, A.3
-
42
-
-
84874096822
-
Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma
-
23407481 10.1097/MPA.0b013e31825e354d 1:CAS:528:DC%2BC3sXis1Kqsrs%3D
-
Poruk KE, Firpo MA, Scaife CL, et al. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 2013;42(2):193-7.
-
(2013)
Pancreas
, vol.42
, Issue.2
, pp. 193-197
-
-
Poruk, K.E.1
Firpo, M.A.2
Scaife, C.L.3
-
43
-
-
77649150762
-
Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology
-
20139773 10.1097/CJI.0b013e3181bed29f
-
Märten A, Büchler MW, Werft W, et al. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother. 2010;33(2):219-24.
-
(2010)
J Immunother
, vol.33
, Issue.2
, pp. 219-224
-
-
Märten, A.1
Büchler, M.W.2
Werft, W.3
-
44
-
-
0028208922
-
Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma
-
8146530 10.1159/000217873 1:STN:280:DyaK2c7ps1ahtA%3D%3D
-
Pasanen PA, Eskelinen M, Partanen K, et al. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma. Tumour Biol. 1994;15(1):52-60.
-
(1994)
Tumour Biol
, vol.15
, Issue.1
, pp. 52-60
-
-
Pasanen, P.A.1
Eskelinen, M.2
Partanen, K.3
-
45
-
-
70349934514
-
Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer
-
19546835 10.1097/MPA.0b013e3181ac5337 1:CAS:528:DC%2BD1MXhtFOjtLvL
-
Eguchi H, Ishikawa O, Ohigashi H, et al. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas. 2009;38(7):791-8.
-
(2009)
Pancreas
, vol.38
, Issue.7
, pp. 791-798
-
-
Eguchi, H.1
Ishikawa, O.2
Ohigashi, H.3
-
46
-
-
4243180461
-
TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis
-
15255543 1:STN:280:DC%2BD2czlt1GqsA%3D%3D
-
Slesak B, Harlozinska-Szmyrka A, Knast W, et al. TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers. 2004;19(2):115-9.
-
(2004)
Int J Biol Markers
, vol.19
, Issue.2
, pp. 115-119
-
-
Slesak, B.1
Harlozinska-Szmyrka, A.2
Knast, W.3
-
47
-
-
84887425166
-
Evolution and dynamics of pancreatic cancer progression
-
doi: 10.1038/onc.2013.2
-
Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene. 2013. doi: 10.1038/onc.2013.2.
-
(2013)
Oncogene
-
-
Yachida, S.1
Iacobuzio-Donahue, C.A.2
-
48
-
-
33846595479
-
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
-
17060676 10.1200/JCO.2006.08.2644 1:CAS:528:DC%2BD28XhtlemurfN
-
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-27.
-
(2006)
J Clin Oncol
, vol.24
, Issue.33
, pp. 5313-5327
-
-
Locker, G.Y.1
Hamilton, S.2
Harris, J.3
-
49
-
-
53549105536
-
Molecular markers of pancreatic cancer: Development and clinical relevance
-
18266003 10.1007/s00423-007-0276-0
-
Fry LC, Mönkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393(6):883-90.
-
(2008)
Langenbecks Arch Surg
, vol.393
, Issue.6
, pp. 883-890
-
-
Fry, L.C.1
Mönkemüller, K.2
Malfertheiner, P.3
-
50
-
-
79951691421
-
Genetic and epigenetic alterations in pancreatic carcinogenesis
-
21886451 10.2174/138920211794520132 1:CAS:528:DC%2BC3MXkslSgtLg%3D
-
Delpu Y, Hanoun N, Lulka H, et al. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 2011;12(1):15-24.
-
(2011)
Curr Genomics
, vol.12
, Issue.1
, pp. 15-24
-
-
Delpu, Y.1
Hanoun, N.2
Lulka, H.3
-
51
-
-
34547830182
-
Molecular pathogenesis of pancreatic cancer: Advances and challenges
-
17691965 10.2174/156652407781387082 1:CAS:528:DC%2BD2sXhtVehsb7I
-
Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med. 2007;7(5):504-21.
-
(2007)
Curr Mol Med
, vol.7
, Issue.5
, pp. 504-521
-
-
Welsch, T.1
Kleeff, J.2
Friess, H.3
-
52
-
-
77954676046
-
Molecular mechanism of pancreatic cancer - Understanding proliferation, invasion, and metastasis
-
20237938 10.1007/s00423-010-0622-5
-
Mihaljevic AL, Michalski CW, Friess H, et al. Molecular mechanism of pancreatic cancer - understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg. 2010;395(4):295-308.
-
(2010)
Langenbecks Arch Surg
, vol.395
, Issue.4
, pp. 295-308
-
-
Mihaljevic, A.L.1
Michalski, C.W.2
Friess, H.3
-
53
-
-
79958045469
-
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways
-
21673986 10.1371/journal.pone.0020537 1:CAS:528:DC%2BC3MXntl2hsr8%3D
-
Wang Z, Banerjee S, Ahmad A, et al. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One. 2011;6(6):e20537.
-
(2011)
PLoS One
, vol.6
, Issue.6
, pp. 20537
-
-
Wang, Z.1
Banerjee, S.2
Ahmad, A.3
-
55
-
-
84862777152
-
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia
-
22226782 10.1053/j.gastro.2011.12.042 1:CAS:528:DC%2BC38XltVyrt7Y%3D
-
Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012 Apr;142(4):730-3.
-
(2012)
Gastroenterology
, vol.142
, Issue.4
, pp. 730-733
-
-
Kanda, M.1
Matthaei, H.2
Wu, J.3
-
56
-
-
84869091997
-
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
-
23103869 10.1038/nature11547 1:CAS:528:DC%2BC38XhsFOmt7jN
-
Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399- 405.
-
(2012)
Nature
, vol.491
, Issue.7424
, pp. 399-405
-
-
Biankin, A.V.1
Waddell, N.2
Kassahn, K.S.3
-
57
-
-
84872065981
-
Oncogenic transcription factors: Cornerstones of inflammation-linked pancreatic carcinogenesis
-
21997559 10.1136/gutjnl-2011-301008 1:CAS:528:DC%2BC3sXislyhsb8%3D
-
Baumgart S, Ellenrieder V, Fernandez-Zapico ME. Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut. 2013 Feb;62(2):310-6.
-
(2013)
Gut
, vol.62
, Issue.2
, pp. 310-316
-
-
Baumgart, S.1
Ellenrieder, V.2
Fernandez-Zapico, M.E.3
-
58
-
-
84875421097
-
Exploiting inflammation for therapeutic gain in pancreatic cancer
-
23385734 10.1038/bjc.2013.24 1:CAS:528:DC%2BC3sXksVKku7s%3D
-
Steele CW, Jamieson NB, Evans TR, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013 Mar 19;108(5):997-1003.
-
(2013)
Br J Cancer
, vol.108
, Issue.5
, pp. 997-1003
-
-
Steele, C.W.1
Jamieson, N.B.2
Evans, T.R.3
-
59
-
-
84872066969
-
Current concepts and novel targets in advanced pancreatic cancer
-
23112132 10.1136/gutjnl-2012-303588 1:CAS:528:DC%2BC3sXislyhsb0%3D
-
Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut. 2013 Feb;62(2):317-26.
-
(2013)
Gut
, vol.62
, Issue.2
, pp. 317-326
-
-
Michl, P.1
Gress, T.M.2
-
60
-
-
84886088469
-
MiRNA in clinical practice: Pancreatic cancer
-
23570860 10.1016/j.clinbiochem.2013.03.019 1:CAS:528:DC%2BC3sXntFahsrk%3D
-
Humeau M, Torrisani J, Cordelier P. miRNA in clinical practice: pancreatic cancer. Clin Biochem. 2013;46(10-11):933-6.
-
(2013)
Clin Biochem
, vol.46
, Issue.10-11
, pp. 933-936
-
-
Humeau, M.1
Torrisani, J.2
Cordelier, P.3
-
61
-
-
84880080446
-
Sweating the small stuff: MicroRNAs and genetic changes define pancreatic cancer
-
23774697 10.1097/MPA.0b013e3182854ab0 1:CAS:528:DC%2BC3sXpvVOks7o%3D
-
Tang S, Bonaroti J, Unlu S, et al. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas. 2013;42(5):740-59.
-
(2013)
Pancreas
, vol.42
, Issue.5
, pp. 740-759
-
-
Tang, S.1
Bonaroti, J.2
Unlu, S.3
-
62
-
-
84879569604
-
A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer
-
23359149 10.1007/978-1-62703-287-2-4
-
Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol. 2013;980:43-59.
-
(2013)
Methods Mol Biol.
, vol.980
, pp. 43-59
-
-
Sempere, L.F.1
Korc, M.2
-
63
-
-
84873748626
-
Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
-
23329235 10.1038/bjc.2012.546 1:CAS:528:DC%2BC3sXis1GnsL4%3D
-
Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013;108(2):361-9.
-
(2013)
Br J Cancer
, vol.108
, Issue.2
, pp. 361-369
-
-
Kawaguchi, T.1
Komatsu, S.2
Ichikawa, D.3
-
64
-
-
84869745207
-
Diagnostic value of microRNA for pancreatic cancer: A meta-analysis
-
23185182 10.5114/aoms.2012.31609 1:CAS:528:DC%2BC3sXitVCltbg%3D
-
Wan C, Shen Y, Yang T, et al. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci. 2012;8(5):749-55.
-
(2012)
Arch Med Sci
, vol.8
, Issue.5
, pp. 749-755
-
-
Wan, C.1
Shen, Y.2
Yang, T.3
-
65
-
-
34247862190
-
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis
-
17473300 10.1001/jama.297.17.1901 1:CAS:528:DC%2BD2sXkvFKru7g%3D
-
Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-8.
-
(2007)
JAMA
, vol.297
, Issue.17
, pp. 1901-1908
-
-
Bloomston, M.1
Frankel, W.L.2
Petrocca, F.3
-
66
-
-
84864327528
-
Circulating microRNAs: Molecular microsensors in gastrointestinal cancer
-
23012546 10.3390/s120709349 1:CAS:528:DC%2BC38XhtVGmtr3P
-
Blanco-Calvo M, Calvo L, Figueroa A. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel). 2012;12(7):9349-62.
-
(2012)
Sensors (Basel).
, vol.12
, Issue.7
, pp. 9349-9362
-
-
Blanco-Calvo, M.1
Calvo, L.2
Figueroa, A.3
-
67
-
-
84862689011
-
MicroRNA signature for human pancreatic cancer invasion and metastasis
-
22970025 1:CAS:528:DC%2BC38Xht1Shu7bI
-
Cheng H, Shi S, Cai X, et al. microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med. 2012;4(2):181-7.
-
(2012)
Exp Ther Med
, vol.4
, Issue.2
, pp. 181-187
-
-
Cheng, H.1
Shi, S.2
Cai, X.3
-
68
-
-
84863505019
-
Molecular pathology and genetics of pancreatic endocrine tumours
-
22586144 10.1530/JME-12-0069 1:CAS:528:DC%2BC38XhtF2jt73K
-
Capurso G, Festa S, Valente R, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol. 2012;49(1):R37-50.
-
(2012)
J Mol Endocrinol
, vol.49
, Issue.1
, pp. 37-50
-
-
Capurso, G.1
Festa, S.2
Valente, R.3
-
69
-
-
33750600178
-
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior
-
16966691 10.1200/JCO.2005.05.5194 1:CAS:528:DC%2BD28XhtFynsr3M
-
Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24(29):4677-84.
-
(2006)
J Clin Oncol
, vol.24
, Issue.29
, pp. 4677-4684
-
-
Roldo, C.1
Missiaglia, E.2
Hagan, J.P.3
-
70
-
-
69949087531
-
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells
-
19714243 10.1371/journal.pone.0006816
-
Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816.
-
(2009)
PLoS One
, vol.4
, Issue.8
, pp. 6816
-
-
Ji, Q.1
Hao, X.2
Zhang, M.3
-
71
-
-
84877060316
-
Targeting miR-21 for the therapy of pancreatic cancer
-
23481326 10.1038/mt.2013.35 1:CAS:528:DC%2BC3sXjslKkurY%3D
-
Sicard F, Gayral M, Lulka H, et al. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013;21(5):986-94.
-
(2013)
Mol Ther
, vol.21
, Issue.5
, pp. 986-994
-
-
Sicard, F.1
Gayral, M.2
Lulka, H.3
-
72
-
-
84862799580
-
Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS
-
22487522 10.1016/j.pan.2012.02.009 1:CAS:528:DC%2BC3sXjtVSht7c%3D
-
Xue A, Gandy RC, Chung L, et al. Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology. 2012;12(2):124-9.
-
(2012)
Pancreatology
, vol.12
, Issue.2
, pp. 124-129
-
-
Xue, A.1
Gandy, R.C.2
Chung, L.3
-
73
-
-
84864508735
-
Proteomics in pancreatic cancer research
-
22084685
-
Geng R, Li Z, Li S, Gao J. Proteomics in pancreatic cancer research. Int J Proteomics. 2011;2011:365350.
-
(2011)
Int J Proteomics
, vol.2011
, pp. 365350
-
-
Geng, R.1
Li, Z.2
Li, S.3
Gao, J.4
-
74
-
-
81855166737
-
Mining the malignant ascites proteome for pancreatic cancer biomarkers
-
21932441 10.1002/pmic.201100264 1:CAS:528:DC%2BC3MXhtlOnurbJ
-
Kosanam H, Makawita S, Judd B, et al. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics. 2011;11(23):4551-8.
-
(2011)
Proteomics
, vol.11
, Issue.23
, pp. 4551-4558
-
-
Kosanam, H.1
Makawita, S.2
Judd, B.3
-
75
-
-
1242328742
-
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer
-
15102462 10.1016/j.copbio.2004.01.005 1:CAS:528:DC%2BD2cXht12jt70%3D
-
Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15(1):24-30.
-
(2004)
Curr Opin Biotechnol
, vol.15
, Issue.1
, pp. 24-30
-
-
Petricoin, E.F.1
Liotta, L.A.2
-
76
-
-
84877819319
-
Strategies for discovering novel pancreatic cancer biomarkers
-
23026552 10.1016/j.jprot.2012.09.025 1:CAS:528:DC%2BC38XhsFWjsLrJ
-
Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics. 2013;81:126-34.
-
(2013)
J Proteomics.
, vol.81
, pp. 126-134
-
-
Chan, A.1
Diamandis, E.P.2
Blasutig, I.M.3
-
77
-
-
84874103152
-
Biomarker discovery of pancreatic and gastrointestinal cancer by 2DICAL: 2-dimensional image-converted analysis of liquid chromatography and mass spectrometry
-
22844596
-
Ono M, Kamita M, Murakoshi Y, et al. Biomarker discovery of pancreatic and gastrointestinal cancer by 2DICAL: 2-dimensional image-converted analysis of liquid chromatography and mass spectrometry. Int J Proteomics. 2012;2012:897412.
-
(2012)
Int J Proteomics.
, vol.2012
, pp. 897412
-
-
Ono, M.1
Kamita, M.2
Murakoshi, Y.3
-
78
-
-
28544446295
-
Possible detection of pancreatic cancer by plasma protein profiling
-
16288055 10.1158/0008-5472.CAN-05-1851 1:CAS:528:DC%2BD2MXht1Wgu73N
-
Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005;65(22):10613-22.
-
(2005)
Cancer Res
, vol.65
, Issue.22
, pp. 10613-10622
-
-
Honda, K.1
Hayashida, Y.2
Umaki, T.3
-
79
-
-
64949148135
-
Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue
-
19357035 1:CAS:528:DC%2BD1MXlt1Ghtbk%3D
-
Chen JH, Ni RZ, Xiao MB, et al. Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int. 2009;8(2):193-200.
-
(2009)
Hepatobiliary Pancreat Dis Int
, vol.8
, Issue.2
, pp. 193-200
-
-
Chen, J.H.1
Ni, R.Z.2
Xiao, M.B.3
-
80
-
-
31644434206
-
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach
-
16215274 10.1074/mcp.M500178-MCP200
-
Grønborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006;5(1):157-71.
-
(2006)
Mol Cell Proteomics
, vol.5
, Issue.1
, pp. 157-171
-
-
Grønborg, M.1
Kristiansen, T.Z.2
Iwahori, A.3
-
81
-
-
84873988737
-
Tissue proteomics in pancreatic cancer study: Discovery, emerging technologies, and challenges
-
23125171 10.1002/pmic.201200319 1:CAS:528:DC%2BC3sXjslektg%3D%3D
-
Pan S, Brentnall TA, Kelly K, et al. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics. 2013;13(3-4):710-21.
-
(2013)
Proteomics
, vol.13
, Issue.3-4
, pp. 710-721
-
-
Pan, S.1
Brentnall, T.A.2
Kelly, K.3
-
82
-
-
79551484371
-
Proteomics in pancreatic cancer research
-
21229586 10.1002/pmic.201000401 1:CAS:528:DC%2BC3MXhsVSntbc%3D
-
Cecconi D, Palmieri M, Donadelli M. Proteomics in pancreatic cancer research. Proteomics. 2011;11(4):816-28.
-
(2011)
Proteomics
, vol.11
, Issue.4
, pp. 816-828
-
-
Cecconi, D.1
Palmieri, M.2
Donadelli, M.3
|